Development of Nodular Lesions after Dupilumab Therapy in Erythrodermic Mycosis Fungoides with Interleukin-13 Receptor alpha2 Expression
Keywords:erythroderma, mycosis fungoides, dupilumab, progression, IL-13 receptor alpha 2
Abstract is missing (Short communication)
Miyagaki T, Sugaya M. Immunological milieu in mycosis fungoides and Sézary syndrome. J Dermatol 2014; 41: 11-18.
Sugaya M. Is blocking IL-4 receptor alpha beneficial for patients with mycosis fungoides or Sézary syndrome? J Dermatol 2021; 48: e225-226.
Elston DM. Dupilumab and cutaneous T-cell lymphoma. J Am Acad Dermatol 2020; 83: 33-34.
Suzuki A, Leland P, Joshi BH, Puri RK. Targeting of IL-4 and IL-13 receptors for cancer therapy. Cytokine 2015; 75: 79-88.
Geskin LJ, Viragova S, Stolz DB, Fuschiotti P. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood 2015; 125: 2798-2805.
Shimamura T, Fujisawa T, Husain SR, Joshi B, Puri RK. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 pseudomonas exotoxin in pancreatic cancer therapy. Clin Cancer Res 2010; 16: 577-586.
Fujisawa T, Joshi BH, Puri RK. IL-13 regulates cancer invasion and metastasis through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int J Cancer 2012; 131: 344-356.
Tu M, Wange W, Cai L, Zhu P, Gao Z, Zheng W. IL-13 receptor alpha2 stimulates human glioma cell growth and metastasis through the Src/PI3K/Akt/mTOR signaling pathway. Tumour Biol 2016; 37: 14701-14709.
Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006; 12: 99-106.
Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001; 20: 2390-2400.
Lazaridou I, Ram-Wolff C, Bouaziz JD, Bégon E, Battistella M, Rivet J, et al. Dupilumab Treatment in Two Patients with Cutaneous T-cell Lymphomas. Acta Derm Venereol 2020; 100: adv00271.
Mollanazar NK, Savage KT, Pousti BT, Jariwala N, Del Guzzo C, Haun P, et al. Cutaneous T-cell lymphoma and concomitant atopic dermatitis responding to dupilumab. Cutis 2020; 106: 131-132.
Steck O, Bertschi NL, Luther F, van den Berg J, Winkel DJ, Holbro A, et al. Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sézary syndrome. J Eur Acad Dermatol Venereol 2021; 35: 1331-1337.
How to Cite
Copyright (c) 2022 Mina Hashimoto, Tomomitsu Miyagaki, Reo Komaki, Sora Takeuchi, Takafumi Kadono
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.